Immatics Reports Interim Clinical Data from Ongoing Phase 1b

Company to host conference calltoday, May 2, at 8:30 am EDT / 2:30 pm CEST Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203

Related Keywords

Germany , Texas , United States , Houston , University Hospital , Martin Wermke , Cedrik Britten , Anja Heuer , Instagramand Linkedin , Charlotte Spitz , Immatic Actengine , University Hospital Dresden , Twitter , European Central Bank , Research Institute Of Texas , Corporate Communications , Trophic Communications , Coordinating Investigator , Chief Medical Officer , Safety Monitoring Board , Overall Response , Neuroendocrine Tumor , Best Overall , All Immatic , Stem Cell Therapeutics Research Laboratory , Cancer Prevention , Research Institute , Adoptive Cell Therapies , Looking Statements , Investor Relations , Trial Application , Investigational New Drug , Immatics , Reports , Interim , Linical , Data , Rom , Ngoing , Hase , Cohort , Monotherapy , Actengine , Ma203 , Targeting , Frame ,